Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.

The curative ability of photodynamic therapy (PDT) is severely compromised if treated tumors are growing in immunodeficient hosts. Reconstitution of severe combined immunodeficient (scid) mice with splenocytes from naive immunologically intact BALB/c mice did not improve the response to Photofrin-based PDT of EMT6 tumors growing in these animals. In contrast, adoptive transfer of BALB/c splenocytes containing EMT6 tumor-sensitized immune cells had a dramatic effect on tumor regrowth after PDT. For instance, full restoration of the curative effect of PDT was achieved with scid mice that received splenocytes from BALB/c donors that were cured of EMT6 tumors by PDT 5 weeks before adoptive transfer. Splenocytes obtained from donors cured of EMT6 tumors using X-rays were much less effective. Selective in vitro depletion of specific T-cell populations from engrafting splenocytes indicated that CTLs are the main immune effector cells responsible for conferring the curative outcome to PDT in this experimental model, whereas helper T lymphocytes play a supportive role. The immune specificity of these T-cell populations was demonstrated by the absence of cross-reactivity between the EMT6 and Meth-A tumor models (mismatch between tumors growing in splenocyte donors and recipients). The immunocompetent BALB/c mice that received adoptively transferred splenocytes containing PDT-generated, tumor-sensitized immune cells also benefited from the improved outcome of PDT of tumors they were bearing. This was demonstrated not only with the fairly immunogenic EMT6 tumor model but also with weakly immunogenic Line 1 carcinomas. The results of this study indicate that PDT is a highly effective means of generating tumor-sensitized immune cells that can be recovered from lymphoid sites distant to the treated tumor at protracted time intervals after PDT, which asserts their immune memory character. It is also shown that the treatment of tumors by PDT creates the conditions necessary for converting the inactive adoptively transferred pre-effector, tumor-sensitized immune cells into fully functional antitumor effector cells. An additional finding of this study is the evidence of NK cell activation in PDT-treated Meth-A sarcomas.

[1]  A. Carroll,et al.  The SCID mouse mutant: definition, characterization, and potential uses. , 1991, Annual review of immunology.

[2]  Q. Peng,et al.  Photodynamic Therapy , 1988, Methods in Molecular Biology.

[3]  R. Blaese,et al.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.

[4]  J. Krauss,et al.  Tumor immunology. , 1997, JAMA.

[5]  J. Hong,et al.  Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo. , 1997, Cancer research.

[6]  B. Henderson,et al.  Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. , 1997, Cancer research.

[7]  U. Nseyo,et al.  Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report. , 1990, Urology.

[8]  Mladen Korbelik,et al.  Cancer treatment by photodynamic therapy combined with NK-cell-line-based adoptive immunotherapy , 1998, Photonics West - Biomedical Optics.

[9]  W. Sluiter,et al.  Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. , 1997, Cancer research.

[10]  L. Old,et al.  ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .

[11]  J. Krauss,et al.  Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. , 1996, Cancer gene therapy.

[12]  Barbara W. Henderson,et al.  Photodynamic therapy affects the expression of IL-6 and IL-10 in vivo , 1998, Photonics West - Biomedical Optics.

[13]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[14]  C J Gomer,et al.  NUCLEAR FACTOR κB BINDING ACTIVITY IN MOUSE L1210 CELLS FOLLOWING PHOTOFRIN II‐MEDIATED PHOTOSENSITIZATION , 1993, Photochemistry and photobiology.

[15]  N. Tamaoki,et al.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. , 1981, Journal of immunology.

[16]  Hasan Mukhtar,et al.  Phthalocyanine Photodynamic Therapy: Disparate Effects of Pharmacologic Inhibitors on Cutaneous Photosensitivity and on Tumor Regression , 1997, Photochemistry and photobiology.

[17]  M. Korbelik,et al.  Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. , 1999, Cancer letters.

[18]  J. Krauss,et al.  Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. , 1996, Cancer research.

[19]  L. F. Fajardo,et al.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. , 1972, Journal of the National Cancer Institute.

[20]  J. Krosl,et al.  The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. , 1996, Cancer research.

[21]  A. Goetz,et al.  Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. , 1995, Cancer research.

[22]  M. Korbelik,et al.  Induction of tumor immunity by photodynamic therapy. , 1996, Journal of clinical laser medicine & surgery.

[23]  C. Gomer,et al.  Cellular targets and molecular responses associated with photodynamic therapy. , 1996, Journal of clinical laser medicine & surgery.